CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 190 filers reported holding CRISPR THERAPEUTICS AG in Q2 2019. The put-call ratio across all filers is 1.08 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $318,000 | +34.2% | 4,200 | +98.4% | 0.01% | +33.3% |
| Q3 2021 | $237,000 | -30.7% | 2,117 | +0.1% | 0.01% | -40.0% |
| Q2 2021 | $342,000 | +165.1% | 2,115 | +37.6% | 0.01% | +66.7% |
| Q3 2020 | $129,000 | -64.6% | 1,537 | -68.9% | 0.01% | -70.0% |
| Q2 2020 | $364,000 | +3.7% | 4,950 | -33.5% | 0.02% | +17.6% |
| Q2 2019 | $351,000 | +17.8% | 7,446 | +46.6% | 0.02% | -10.5% |
| Q2 2018 | $298,000 | -41.5% | 5,078 | -54.4% | 0.02% | -48.6% |
| Q1 2018 | $509,000 | -13.6% | 11,131 | -55.7% | 0.04% | -21.3% |
| Q4 2017 | $589,000 | – | 25,106 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |